Bydureon is a once-weekly type-2 diabetes drug that is the extended-release version of Byetta (exenatide). Recently, the FDA has warned that Bydureon and other drugs in its class may increase the risk of pancreatitis (pancreatic inflammation), which is a risk-factor for pancreatic cancer. The FDA has also required a “Black Box” warning about the risk of thyroid cancer from Bydureon.
Free Bydureon Lawsuit Evaluation: If you or your loved one was injured by Bydureon, contact our law firm immediately for a free case consultation. If you file a lawsuit, you could receive compensation for your injury, medical expenses, and more.
Bydureon Lawsuit Information
In 2008, Michael E. Schmidt filed the first-ever lawsuit involving exenatide. The plaintiff, a man from Virginia, developed pancreatitis after taking Byetta. The lawsuit was filed in San Diego Superior Court — the same city where drug-maker Amylin Pharmaceuticals was headquartered until April 2013.
Currently, at least 53 lawsuits are centralized in San Diego in a Multi-District Litigation (MDL), which is similar to a class action lawsuit. Bydureon lawsuits could also be centralized in the litigation: In RE: Incretin Mimetics Products Liability Litigation; MDL No. 2452.
Although the MDL is often confused with a class action, it is different because each plaintiff who files an individual lawsuit that can potentially go to trial. If compensation is awarded, it is not shared with other plaintiffs.
Bydureon lawsuits could be compensated for:
- Pain and suffering (emotional and physical)
- Medical expenses
- Lost income or employment
- Permanent disability
- Loss of a loved one
- Punitive damages
What’s the problem with Bydureon?
Bydureon (extended-release exenatide) is one of the newest type-2 diabetes drugs in the “incretin mimetic” class. It is a once-weekly injection drug that is designed to stimulate the pancreas to increase production of insulin. Although directly targeting the pancreas is a good way to lower blood-sugar, Bydureon may also have adverse effects — including pancreatic cancer.
In 2007, the FDA warned that exenatide may increase the risk of pancreatitis (pancreatic inflammation). Many experts are concerned about the link between Bydureon and pancreatitis. It is possible that long-term use of Bydureon could increase the risk of low-level, asymptomatic pancreatitis. Chronic pancreatitis significantly increases a person’s risk of pancreatic cancer.
Studies of Bydureon and Pancreatic Cancer
Numerous studies are investigating the link between Bydureon and pancreatic cancer. Before Bydureon was approved, exenatide was linked to a 2.9-fold increased risk of pancreatic cancer in this study published in Gastroenterology in 2010. Researchers from UCLA linked exenatide to 81 cases of pancreatic cancer between 2004-2009.
In March 2013, the FDA published a Drug Safety Communication to warn that Bydureon and other drugs in the “incretin mimetic” class may be associated with pre-cancerous cellular changes in the pancreas. The FDA was concerned about a study published in Diabetes linking exenatide to pancreatic tumors. Researchers warned:
“Since the standard of care of a pancreatic neuroendocrine tumor, because of the risk of conversion to malignancy, even if benign, is surgical resection [i.e. removal], patients exposed to incretin therapy would seem to be at increased risk of requiring pancreatic surgery.”
Do I have a Bydureon Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Bydureon lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Bydureon Lawsuit Evaluation: Again, if you or a loved one was injured by Bydureon, you should contact our law firm immediately. You could be entitled to compensation by filing a Bydureon lawsuit, and our lawyers can help.